Ontology highlight
ABSTRACT: Introduction
Data on tumor immune-milieu after chemo-radiation (CT-RT) are scarce. Noninvasive tools are needed to improve the treatment of non-small cell lung cancer (NSCLC), especially in the locally advanced (LA) setting.Methods
We collected a series of superior-sulcus (SS)- patients with NSCLC referred to our Institute (2015-2019), eligible for a preoperative CT-RT. We characterized tumor-infiltrating immune cells (TIICs), determined PD-L1-TPS and the residual viable tumor cells (RVTC). Radiological and metabolic responses were reviewed. We calculated pre-surgery neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR).Results
Eight patients were included. Radiological responses were 6 disease stabilities (SD) and 2 partial responses (PR). Metabolic responses were 4 SD and 4 PR. CD68+-TIICs were correlated with metabolic response and lower RVTC. CD68+-TIICs were associated with higher PLR. Higher PLR values seemed linked with lower RVTC.Conclusions
These preliminary results could be useful for consolidation treatment selection for patients with LA-NSCLC without evaluable baseline PD-L1 and higher PLR values.
SUBMITTER: Pavan A
PROVIDER: S-EPMC8895738 | biostudies-literature | 2022 Mar
REPOSITORIES: biostudies-literature
Pavan Alberto A Ferro Alessandra A Fortarezza Francesco F Schiavon Marco M Evangelista Laura L Pezzuto Federica F Lunardi Francesca F Frega Stefano S Bonanno Laura L Rea Federico F Guarneri Valentina V Conte PierFranco P Calabrese Fiorella F Pasello Giulia G
The oncologist 20220301 2
<h4>Introduction</h4>Data on tumor immune-milieu after chemo-radiation (CT-RT) are scarce. Noninvasive tools are needed to improve the treatment of non-small cell lung cancer (NSCLC), especially in the locally advanced (LA) setting.<h4>Methods</h4>We collected a series of superior-sulcus (SS)- patients with NSCLC referred to our Institute (2015-2019), eligible for a preoperative CT-RT. We characterized tumor-infiltrating immune cells (TIICs), determined PD-L1-TPS and the residual viable tumor ce ...[more]